Companies
/
Xaira Therapeutics
Artificial Intelligence
Healthtech
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Xaira Therapeutics is an AI-native biotechnology company leveraging generative models and proprietary data to reinvent drug discovery by shifting from empirical screening to engineering medicines from the ground up.
Xaira Therapeutics was founded in 2024 by a team including Marc Tessier-Lavigne, a former Stanford University president and prominent neuroscientist, together with a group of leading AI and computational biology researchers, launching with an extraordinarily large initial funding round of approximately $1 billion, one of the largest amounts ever raised by a biotechnology company at its founding (per public reporting at launch), reflecting significant investor interest in AI-enabled drug discovery of AI-driven protein structure prediction and design technology, building on the foundational breakthrough represented by DeepMind's AlphaFold system for predicting protein three-dimensional structures, with drug discovery applications that Xaira and several other well-funded competitors are racing to commercialize.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
| Company | Valuation |
|---|---|
Open Anthropic Artificial Intelligence | $1.39T |
Open OpenAI Artificial Intelligence | $1.2T |
Open Neuralink Healthtech | $51.4B |
Open Cognition AI (Devin) Artificial Intelligence | $60.6B |
Open Prometheus Artificial Intelligence | $42.8B |
Sign up with Augment to see the latest market activity.
